IL204948A - Β - single ifn from one to a mutated fc lgg segment - Google Patents

Β - single ifn from one to a mutated fc lgg segment

Info

Publication number
IL204948A
IL204948A IL204948A IL20494810A IL204948A IL 204948 A IL204948 A IL 204948A IL 204948 A IL204948 A IL 204948A IL 20494810 A IL20494810 A IL 20494810A IL 204948 A IL204948 A IL 204948A
Authority
IL
Israel
Prior art keywords
lgg
mutated
fragment
fused
single ifn
Prior art date
Application number
IL204948A
Other languages
English (en)
Hebrew (he)
Other versions
IL204948A0 (en
Inventor
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Phillippe Dupraz
Christine Power
Laurent Magenant
Phillippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Original Assignee
Merck Serono Sa
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Phillippe Dupraz
Christine Power
Laurent Magenant
Phillippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa, Peter Hjelmstrom, Markus Imhof, George Feger, Nigel Jenkins, Phillippe Dupraz, Christine Power, Laurent Magenant, Phillippe Chatellard, Renata Pankiewicz, Vincent Dechavanne filed Critical Merck Serono Sa
Publication of IL204948A0 publication Critical patent/IL204948A0/en
Publication of IL204948A publication Critical patent/IL204948A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL204948A 2007-10-22 2010-04-08 Β - single ifn from one to a mutated fc lgg segment IL204948A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118980 2007-10-22
US714207P 2007-12-11 2007-12-11
PCT/EP2008/064224 WO2009053368A1 (en) 2007-10-22 2008-10-21 Single ifn-beta fused to a mutated igg fc fragment

Publications (2)

Publication Number Publication Date
IL204948A0 IL204948A0 (en) 2010-11-30
IL204948A true IL204948A (en) 2015-11-30

Family

ID=39048918

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204948A IL204948A (en) 2007-10-22 2010-04-08 Β - single ifn from one to a mutated fc lgg segment

Country Status (6)

Country Link
EP (1) EP2203180B1 (OSRAM)
JP (1) JP5314033B2 (OSRAM)
AU (1) AU2008314697B2 (OSRAM)
ES (1) ES2400107T3 (OSRAM)
IL (1) IL204948A (OSRAM)
WO (1) WO2009053368A1 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646792T3 (es) 2002-01-25 2017-12-18 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US9493543B2 (en) 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
SI2591006T1 (sl) * 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
MX349057B (es) * 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
RU2616881C2 (ru) 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
WO2013011062A2 (en) * 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
MX359775B (es) 2011-10-31 2018-10-10 Chugai Pharmaceutical Co Ltd Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada.
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
MX382731B (es) 2013-09-27 2025-03-13 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
JP6894702B2 (ja) 2014-05-13 2021-06-30 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
LT3221363T (lt) * 2014-11-21 2020-08-10 Bristol-Myers Squibb Company Antikūnai prieš cd73 ir jų panaudojimas
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
HUE064791T2 (hu) 2015-11-25 2024-04-28 Visterra Inc APRIL ellenes antitest molekulák és alkalmazásaik
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
CA3010056A1 (en) * 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
WO2017159287A1 (ja) 2016-03-14 2017-09-21 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
US20220041719A1 (en) * 2018-12-05 2022-02-10 Morphosys Ag Multispecific antigen-binding molecules
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01003790A (es) * 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2006207471A1 (en) * 2005-01-24 2006-07-27 Laboratoires Serona S.A. Use of soluble CD164 variants in inflammatory and/or autoimmune disorders
US20060269516A1 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-IgG fusion

Also Published As

Publication number Publication date
EP2203180A1 (en) 2010-07-07
AU2008314697B2 (en) 2013-08-29
JP2011500073A (ja) 2011-01-06
AU2008314697A1 (en) 2009-04-30
JP5314033B2 (ja) 2013-10-16
IL204948A0 (en) 2010-11-30
EP2203180B1 (en) 2012-11-21
WO2009053368A1 (en) 2009-04-30
ES2400107T3 (es) 2013-04-05

Similar Documents

Publication Publication Date Title
IL204948A (en) Β - single ifn from one to a mutated fc lgg segment
EP2118129A4 (en) ISOLATED PHOSPHOLIPID PROTEIN PARTICLES
EP2448972A4 (en) IMMUNOGLOBULIN FC POLYPEPTIDES
IL202128A0 (en) Immunoglobulin fusion proteins
ZA200908649B (en) Rage fusion proteins
IL201791A (en) Interferon-adapted polypeptides in the cell
PL3118220T3 (pl) Białko
GB0721686D0 (en) Polypeptides
SI2173381T1 (sl) Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
IL202441A0 (en) Glass ceramic armor material
ZA201000283B (en) Reinigung pegylierter polypeptide
PL2144924T3 (pl) Szczepionka z białkiem fuzyjnym
GB2445928B (en) Retractable handle assembly
GB0725153D0 (en) Protein analysis
GB0719231D0 (en) Protein
GB0715957D0 (en) Saftey switch
GB0725201D0 (en) Peptide fusion proteins
GB0712302D0 (en) Chrondroitinase polypeptides
GB0719492D0 (en) Grinder for electrodes
GB0700759D0 (en) Novel fusion protein
TWI320491B (en) Multifunctional glasses
GB0720563D0 (en) Protein
GB0805426D0 (en) handle
GB0709707D0 (en) Novel fusion protein
GB0713169D0 (en) Fusion proteins

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)